180 Life Sciences (NASDAQ:ATNF) Earns “Sell (E+)” Rating from Weiss Ratings

180 Life Sciences (NASDAQ:ATNF)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

180 Life Sciences Stock Performance

Shares of NASDAQ:ATNF opened at $1.28 on Wednesday. 180 Life Sciences has a 52 week low of $1.16 and a 52 week high of $17.75. The company’s fifty day moving average is $1.64 and its 200-day moving average is $2.11.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in 180 Life Sciences stock. Anson Funds Management LP purchased a new position in shares of 180 Life Sciences Corp. (NASDAQ:ATNF) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 225,271 shares of the company’s stock, valued at approximately $410,000. Anson Funds Management LP owned approximately 7.08% of 180 Life Sciences as of its most recent SEC filing. Hedge funds and other institutional investors own 4.07% of the company’s stock.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.